| Oct 28 |
Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
|
| Oct 27 |
Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
|
| Oct 14 |
Longeveron® Lomecel-B™ Data in Alzheimer’s Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24)
|
| Oct 9 |
Longeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting
|
| Oct 7 |
Longeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy Day
|
| Oct 2 |
Longeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
|
| Sep 26 |
Longeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the Mesa
|
| Sep 3 |
Longeveron® Announces Positive Type C Meeting with U.S. FDA Regarding Pathway to BLA for Lomecel-B™ in Hypoplastic Left Heart Syndrome (HLHS)
|
| Aug 26 |
Longeveron to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 25 |
Wall Street Breakfast: The Week Ahead
|
